CASP3 and metabolic dysfunction-associated steatotic liver disease: Sun and their research team (Sun, et al., 2022a) found that there were 48 intersection targets of Cynarine and NAFLD, among which TP53, ELANE, MMP9, CASP3, and NOTCH1 were the core therapeutic targets.